49 research outputs found

    On the minimal number of matrices which form a locally hypercyclic, non-hypercyclic tuple

    Get PDF
    In this paper we extend the notion of a locally hypercyclic operator to that of a locally hypercyclic tuple of operators. We then show that the class of hypercyclic tuples of operators forms a proper subclass to that of locally hypercyclic tuples of operators. What is rather remarkable is that in every finite dimensional vector space over R\mathbb{R} or C\mathbb{C}, a pair of commuting matrices exists which forms a locally hypercyclic, non-hypercyclic tuple. This comes in direct contrast to the case of hypercyclic tuples where the minimal number of matrices required for hypercyclicity is related to the dimension of the vector space. In this direction we prove that the minimal number of diagonal matrices required to form a hypercyclic tuple on Rn\mathbb{R}^n is n+1n+1, thus complementing a recent result due to Feldman.Comment: 15 pages, title changed, section for infinite dimensional spaces adde

    Assessment of apoptosis in human breast tissue using an antibody against the active form of caspase 3: relation to tumour histopathological characteristics

    Get PDF
    Apoptosis is of important significance in the pathogenesis of cancer. Many methods are available for the measurement of apoptosis but the ‘gold standard’ is to identify apoptotic cells by their morphological features using microscopy. Caspase 3 is a cytosolic enzyme that is activated only in cells committed to undergo apoptosis. The activation of caspase 3 precedes the development of the classical morphological features of apoptosis. Using immunohistochemistry with an antibody against the active form of caspase 3, the apoptotic index (AI) was measured in 116 samples of human breast tissue (22 normal/benign and 94 invasive carcinomas). The AI obtained by measuring caspase activation has a strong correlation with the AI derived by morphological assessment (r = 0.736, P < 0.01). The AI is higher in the invasive group than in the benign group (P = 0.008), and in invasive cancer high AI is associated with high tumour grade (P = 0.013), positive node status (P < 0.001) and negative steroid receptor status (P = 0.001 for ER; P = 0.004 for PR). No significant association is observed between AI and tumour size. Measurement of apoptosis by immunohistochemistry using an antibody against the active form of caspase 3 is therefore reliable and correlates strongly with morphological assessment. © 2001 Cancer Research Campaign  http://www.bjcancer.co

    Apoptosis in human tumours

    Get PDF
    British Journal of Cancer (2002) 86, 1661–1661 DOI: 10.1038/sj/bjc/6600312 www.bjcancer.co

    Will early detection of non-axillary sentinel nodes affect treatment decisions?

    Get PDF
    Axillary lymph node involvement is the best prognostic factor for breast cancer survival. Staging breast cancers by axillary dissection remains standard management and is part of the UK national guidelines for breast cancer treatment. In the presence of involved axillary lymph nodes best treatment has been shown to be axillary clearance (Fentiman and Mansell, 1991), but clearly for women whose nodes are uninvolved avoidance of morbidity is optimal and this will be achieved by minimal dissection of the axilla. Thus, for node-negative women the introduction of the sentinel node biopsy technique may revolutionise the approach to the axilla. These will be women with mammographic screen detected small well and moderately differentiated tumours (Hadjiloucas and Bundred, 2000). The impact of sentinel node biopsy in women who have symptomatic large tumours is unproven, and around half of these women will require a second procedure to clear their axilla or radiotherapy as treatment. Even for those women found to have involved sentinel lymph nodes the ability to use early systemic chemotherapy followed by axillary clearance or radiotherapy may provide long-term survival gains. Sentinel node biopsy should not, however, become routine practice until randomised controlled trials have proven its benefit and safety in reducing morbidity. Several randomised controlled trials (including ALMANAC) are currently underway
    corecore